

Nicolas Noel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9122940/publications.pdf>

Version: 2024-02-01

45
papers

4,048
citations

471509

17
h-index

243625

44
g-index

52
all docs

52
docs citations

52
times ranked

8462
citing authors

#	ARTICLE	IF	CITATIONS
1	Parvovirus B19-related peripheral nerve necrotizing vasculitis following SARS-CoV-2 infection. <i>Revue Neurologique</i> , 2022, 178, 158-160.	1.5	3
2	Immune interventions in COVID-19: a matter of time?. <i>Mucosal Immunology</i> , 2022, 15, 198-210.	6.0	14
3	Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. <i>Lancet Rheumatology</i> , The, 2022, 4, e24-e32.	3.9	34
4	Respiratory symptoms and radiological findings in post-acute COVID-19 syndrome. <i>ERJ Open Research</i> , 2022, 8, 00479-2021.	2.6	16
5	Post-acute COVID-19 syndrome. <i>European Respiratory Review</i> , 2022, 31, 210185.	7.1	105
6	Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia. <i>JAMA Internal Medicine</i> , 2021, 181, 32.	5.1	654
7	Severe ulcerative gastrointestinal toxicity following ibrutinib therapy: two case studies. <i>Leukemia and Lymphoma</i> , 2021, 62, 984-987.	1.3	2
8	Inflammatory demyelinating polyneuropathies and lymphoma: clues to diagnosis and therapy. <i>Leukemia and Lymphoma</i> , 2021, 62, 2000-2004.	1.3	1
9	Severe IgA-mediated autoimmune hemolytic anemia triggered by SARS-CoV-2 infection. <i>Leukemia and Lymphoma</i> , 2021, 62, 2037-2039.	1.3	3
10	Four-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1525.	7.4	434
11	Multidisciplinary approach for post-acute COVID-19 syndrome: time to break down the walls. <i>European Respiratory Journal</i> , 2021, 58, 2101090.	6.7	18
12	CXCR3 and CXCR5 are highly expressed in HIV-1-specific CD8 central memory T cells from infected patients. <i>European Journal of Immunology</i> , 2021, 51, 2040-2050.	2.9	2
13	Pulmonary Hypertension in Patients with Common Variable Immunodeficiency. <i>Journal of Clinical Immunology</i> , 2021, 41, 1549-1562.	3.8	3
14	Antiretroviral therapy for HIV controllers: Reasons for initiation and outcomes in the French ANRS-CO21 CODEX cohort. <i>EClinicalMedicine</i> , 2021, 37, 100963.	7.1	5
15	Anti-Ma2 antibody encephalitis associated with Sjogren's syndrome. <i>Revue De Medecine Interne</i> , 2021, 42, 575-578.	1.0	1
16	Discovery of Anti-SS-A Antibodies during Stroke Investigations in Young Adults: What Impact?. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021, 30, 105896.	1.6	0
17	Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelae. <i>Brain Communications</i> , 2021, 3, fcab220.	3.3	16
18	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). <i>Journal of Hematology and Oncology</i> , 2021, 14, 168.	17.0	189

#	ARTICLE	IF	CITATIONS
19	Hepatitis C virus or hepatitis B virus coinfection and lymphoma risk in people living with HIV. <i>Aids</i> , 2020, 34, 599-608.	2.2	7
20	Clinical characteristics, management and outcome of COVID-19-associated immune thrombocytopenia: a French multicentre series. <i>British Journal of Haematology</i> , 2020, 190, e224-e229.	2.5	68
21	Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation. <i>European Respiratory Journal</i> , 2020, 56, 2001875.	6.7	90
22	Infectious complications in patients treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2020, 141, 137-142.	2.8	24
23	Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: a patient-centred approach. <i>Internal and Emergency Medicine</i> , 2020, 15, 587-598.	2.0	16
24	HIV controllers: to treat or not to treat? Is that the right question?. <i>Lancet HIV</i> , 2019, 6, e878-e884.	4.7	13
25	Cold agglutinin disease as a new immune-related adverse event associated with anti-PD-L1s and its treatment with rituximab. <i>European Journal of Cancer</i> , 2019, 110, 21-23.	2.8	10
26	Cardiovascular Events in the French ANRS HIV Controller Cohort. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, e32-e34.	2.1	9
27	Dynamics in HIV RNA levels over time in HIV controllers. <i>Journal of the International AIDS Society</i> , 2019, 22, e25221.	3.0	21
28	Interferon-associated therapies toward HIV control: The back and forth. <i>Cytokine and Growth Factor Reviews</i> , 2018, 40, 99-112.	7.2	17
29	Effect of CRP value on 18F-FDG PET vascular positivity in Takayasu arteritis: a systematic review and per-patient based meta-analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 575-581.	6.4	17
30	Motivational interviewing training for medical students: A pilot pre-post feasibility study. <i>Patient Education and Counseling</i> , 2018, 101, 1934-1941.	2.2	12
31	Systemic DPP^4 activity is reduced during primary HIV-1 infection and is associated with intestinal RORC^+ CD^4 cell levels: a surrogate marker candidate of HIV-induced intestinal damage. <i>Journal of the International AIDS Society</i> , 2018, 21, e25144.	3.0	16
32	Eosinophil-rich tissue infiltrates in chronic myelomonocytic leukemia patients. <i>Leukemia and Lymphoma</i> , 2017, 58, 2875-2879.	1.3	3
33	A Subset of Extreme Human Immunodeficiency Virus (HIV) Controllers Is Characterized by a Small HIV Blood Reservoir and a Weak T-Cell Activation Level. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx064.	0.9	45
34	Efficacy and Tolerance of Anti-Tumor Necrosis Factor Agents in Cutaneous Sarcoidosis. <i>JAMA Dermatology</i> , 2017, 153, 681.	4.1	46
35	Recurrent obstructive acute pyelonephritis: A rare form of <i>Actinotignum (Actinobaculum) schaalii</i> infection in a HIV-1 infected patient. <i>Anaerobe</i> , 2017, 43, 75-77.	2.1	6
36	Strong <i>ifitm1</i> Expression in CD4 T Cells in HIV Controllers Is Correlated With Immune Activation. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, e56-e59.	2.1	7

#	ARTICLE	IF	CITATIONS
37	Elevated Basal Pre-infection CXCL10 in Plasma and in the Small Intestine after Infection Are Associated with More Rapid HIV/SIV Disease Onset. <i>PLoS Pathogens</i> , 2016, 12, e1005774.	4.7	50
38	Long-Term Spontaneous Control of HIV-1 Is Related to Low Frequency of Infected Cells and Inefficient Viral Reactivation. <i>Journal of Virology</i> , 2016, 90, 6148-6158.	3.4	50
39	Disseminated intravascular coagulation following administration of sunitinib. <i>Molecular and Clinical Oncology</i> , 2016, 5, 121-123.	1.0	1
40	Immune-related adverse events with immune checkpoint blockade: a comprehensive review. <i>European Journal of Cancer</i> , 2016, 54, 139-148.	2.8	1,687
41	Life-threatening Hughes-Stovin syndrome: The Yin and Yang of anticoagulation therapy. <i>Joint Bone Spine</i> , 2016, 83, 459-460.	1.6	5
42	Adipose Tissue Is a Neglected Viral Reservoir and an Inflammatory Site during Chronic HIV and SIV Infection. <i>PLoS Pathogens</i> , 2015, 11, e1005153.	4.7	191
43	Immunologic and Virologic Progression in HIV Controllers: The Role of Viral "Blips" and Immune Activation in the ANRS CO21 CODEX Study. <i>PLoS ONE</i> , 2015, 10, e0131922.	2.5	50
44	Elevated IP10 levels are associated with immune activation and low CD4+ T-cell counts in HIV controller patients. <i>Aids</i> , 2014, 28, 467-476.	2.2	85
45	Renal involvement of lymphomas proven by kidney biopsy: report of 10 cases from a tertiary care center and comparison with the literature. <i>International Journal of Hematology</i> , 0, , .	1.6	0